Quetiapine in adolescents with psychosis: a 12 weeks open label trial
Details
Serval ID
serval:BIB_08A52DBB190A
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Quetiapine in adolescents with psychosis: a 12 weeks open label trial
Title of the conference
Schizophrenia Research
ISBN
0920-9964
Publication state
Published
Issued date
2008
Peer-reviewed
Oui
Volume
98
Series
Schizophrenia Research
Pages
162
Language
english
Notes
SAPHIRID:68311
Abstract
Background: Clinical effectiveness, tolerability and pharmacokinetics of quetiapine in adolescents with psychotic disorders have been established, but cognitive functions have not yet been examined specifically in this population.
Methods: We assessed 23 adolescents (13-18 years old) with psychotic disorders participated in a 12-week open-label trial assessing clinical efficacy, tolerability and impact on cognitive functions of quetiapine (50-750 mg daily).
Results: Adolescents were treated with lower doses compared to adults, a decrease in Clinical Global Impression (CGI) and Positive and Negative Syndrome Scale (PANSS) total score was observed while neuropsychological functioning remained stable after 12 weeks of quetiapine treatment.
Conclusions: Quetiapine is an effective and well tolerated treatment in adolescents with psychotic disorders, no improvement in cognitive functioning has been observed in this trial.
Methods: We assessed 23 adolescents (13-18 years old) with psychotic disorders participated in a 12-week open-label trial assessing clinical efficacy, tolerability and impact on cognitive functions of quetiapine (50-750 mg daily).
Results: Adolescents were treated with lower doses compared to adults, a decrease in Clinical Global Impression (CGI) and Positive and Negative Syndrome Scale (PANSS) total score was observed while neuropsychological functioning remained stable after 12 weeks of quetiapine treatment.
Conclusions: Quetiapine is an effective and well tolerated treatment in adolescents with psychotic disorders, no improvement in cognitive functioning has been observed in this trial.
Create date
23/06/2008 15:01
Last modification date
20/08/2019 12:30
Usage data
